We then analyzed the immune cell composition within the tumors, and while no difference in the numbers of tumor‐infiltrating lymphocytes (CD45+CD3+) was observed between the different treatment arms (Fig. 5D), there was a statistically significant enrichment of CD45+CD3− cells in tumors treated with the MEKi/anti‐CD73 antibody combination compared to those treated with vehicle and MEKi alone (Fig. 5E). The gene discussed is PTPRC; the disease is neoplasm.